Alexander P. Andersohn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander P. Andersohn has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Abdikarim Abdullahi
Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
1 shared publicationAndrea N. Doan
Department of Neurology, University of Texas McGovern Medical School at Houston, Houston, TX, USA
1 shared publicationAskar M. Akimzhanov
Department of Biochemistry and Molecular Biology, McGovern Medical School at UTHealth, Houston, TX, United States
1 shared publicationCharles L. Cantrell
Natural Products Utilization Research Unit, Agricultural Research Service, United States Department of Agriculture, University, MS, 38677, USA
1 shared publication- Darren Boehning
Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, USA
1 shared publication Gab S. Kim
Department of Neurology, University of Texas McGovern Medical School at Houston, Houston, TX, USA
1 shared publication
Latest Publications
- Open Access
Capsinoids (non-pungent TRPV1 agonists) promote mild hypothermia and improved outcome following stroke in aged mice
Background and Purpose: Mild hypothermia provides potent neuroprotection in experimental ischemic stroke, however, its implementation in awake stroke patients is hampered by the induction of intense shivering and inconsistent body temperature control. Pharmacological activation of peripheral/peritoneal TRPV1 channels with non-pungent capsinoids offers a means to induce hypothermia while minimizing TRPV1 activation in the injury region. We tested whether capsinoid-mediated mild hypothermia, initiated within the post-stroke period, reduces brain injury and improves functional outcomes in aged mice. Methods: Aged (18–20 months) male and female C57BL/6 mice underwent either permanent distal middle cerebral artery (MCA) occlusion (pdMCAO) or 60-minute MCA occlusion/reperfusion (MCAO/R). At 2 or 4 hours after stroke, mice received intraperitoneal injections of vehicle or capsinoids (>97% purity; 40 mg/kg) every 90 minutes to induce mild hypothermia for 4.5–6 hours. Core temperature was monitored by wireless probe. After pdMCAO, infarct volume was quantified at post-stroke day 3 (PSD3) by TTC and brain atrophy at PSD30 by iodine-enhanced microCT; sensorimotor function (DigiGait, forelimb grip strength, foot fault) was assessed at PSD7 and PSD30. Survival was the primary measured outcome for MCAO/R. Results: Capsinoids induced a rapid and sustained reduction in core temperature of 2–4°C, independent of sex. In the pdMCAO model, capsinoid-induced hypothermia reduced infarct volume by 48% at PSD3 and decreased chronic cortical tissue loss by 44% at PSD30. Capsinoid-treated mice showed significant improvements in gait, grip strength, and contralateral foot fault performance at PSD7 and PSD30. In the MCAO/R model, survival was significantly higher in capsinoid-treated mice (80%) versus vehicle controls (33%) through PSD3. Conclusions: Intraperitoneal capsinoid administration after stroke induces mild hypothermia in aged mice and confers robust acute neuroprotection and improved chronic functional outcome and survival. These preclinical findings add support for the use of capsinoids as a means to target peripheral thermoeffectors for promoting neuroprotective hypothermia in conscious stroke subjects.
Open AccessCapsinoids (non-pungent TRPV1 agonists) promote mild hypothermia and improved outcome following stroke in aged mice
Background and Purpose: Mild hypothermia provides potent neuroprotection in experimental ischemic stroke, however, its implementation in awake stroke patients is hampered by the induction of intense shivering and inconsistent body temperature control. Pharmacological activation of peripheral/peritoneal TRPV1 channels with non-pungent capsinoids offers a means to induce hypothermia while minimizing TRPV1 activation in the injury region. We tested whether capsinoid-mediated mild hypothermia, initiated within the post-stroke period, reduces brain injury and improves functional outcomes in aged mice. Methods: Aged (18–20 months) male and female C57BL/6 mice underwent either permanent distal middle cerebral artery (MCA) occlusion (pdMCAO) or 60-minute MCA occlusion/reperfusion (MCAO/R). At 2 or 4 hours after stroke, mice received intraperitoneal injections of vehicle or capsinoids (>97% purity; 40 mg/kg) every 90 minutes to induce mild hypothermia for 4.5–6 hours. Core temperature was monitored by wireless probe. After pdMCAO, infarct volume was quantified at post-stroke day 3 (PSD3) by TTC and brain atrophy at PSD30 by iodine-enhanced microCT; sensorimotor function (DigiGait, forelimb grip strength, foot fault) was assessed at PSD7 and PSD30. Survival was the primary measured outcome for MCAO/R. Results: Capsinoids induced a rapid and sustained reduction in core temperature of 2–4°C, independent of sex. In the pdMCAO model, capsinoid-induced hypothermia reduced infarct volume by 48% at PSD3 and decreased chronic cortical tissue loss by 44% at PSD30. Capsinoid-treated mice showed significant improvements in gait, grip strength, and contralateral foot fault performance at PSD7 and PSD30. In the MCAO/R model, survival was significantly higher in capsinoid-treated mice (80%) versus vehicle controls (33%) through PSD3. Conclusions: Intraperitoneal capsinoid administration after stroke induces mild hypothermia in aged mice and confers robust acute neuroprotection and improved chronic functional outcome and survival. These preclinical findings add support for the use of capsinoids as a means to target peripheral thermoeffectors for promoting neuroprotective hypothermia in conscious stroke subjects.
- Open Access
- 18 September 2019
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 7, 198
Aggregated and Hyperstable Damage-Associated Molecular Patterns Are Released During ER Stress to Modulate Immune Function
Chronic ER stress occurs when protein misfolding in the Endoplasmic reticulum (ER) lumen remains unresolved despite activation of the unfolded protein response. We have shown that traumatic injury such as a severe burn leads to chronic ER stress in vivo leading to systemic inflammation which can last for more than a year. The mechanisms linking chronic ER stress to systemic inflammatory responses are not clear. Here we show that induction of chronic ER stress leads to the release of known and novel damage-associated molecular patterns (DAMPs). The secreted DAMPs are aggregated and markedly protease resistant. ER stress-derived DAMPs activate dendritic cells (DCs) which are then capable of polarizing naïve T cells. Our findings indicate that induction of chronic ER stress may lead to the release of hyperstable DAMPs into the circulation resulting in persistent systemic inflammation and adverse outcomes.
- 18 September 2019
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 7, 198
Open AccessAggregated and Hyperstable Damage-Associated Molecular Patterns Are Released During ER Stress to Modulate Immune Function
Chronic ER stress occurs when protein misfolding in the Endoplasmic reticulum (ER) lumen remains unresolved despite activation of the unfolded protein response. We have shown that traumatic injury such as a severe burn leads to chronic ER stress in vivo leading to systemic inflammation which can last for more than a year. The mechanisms linking chronic ER stress to systemic inflammatory responses are not clear. Here we show that induction of chronic ER stress leads to the release of known and novel damage-associated molecular patterns (DAMPs). The secreted DAMPs are aggregated and markedly protease resistant. ER stress-derived DAMPs activate dendritic cells (DCs) which are then capable of polarizing naïve T cells. Our findings indicate that induction of chronic ER stress may lead to the release of hyperstable DAMPs into the circulation resulting in persistent systemic inflammation and adverse outcomes.